Related Experiment Videos
Effects of FK3311 on pulmonary ischemia-reperfusion injury in a canine model
Y Sunose1, I Takeyoshi, H Tsutsumi
1Second Department of Surgery, Gunma University School of Medicine, 3-39-15 Showa-Machi, Gunma, Maebashi, 371-8511, Japan.
Background:
This study investigated the effects of a selective COX-2 inhibitor, FK3311, on warm ischemia-reperfusion (I/R) injury in the canine lung.
Materials And Methods:
Sixteen adult mongrel dogs were used in this study. In the FK group (n = 8), FK (1 mg/kg) was administered intravenously 15 min before ischemia and 15 min before reperfusion. In the control group (n = 8), a vehicle was injected in the same manner. Warm ischemia was induced for 3 h by clamping the left pulmonary artery, veins, and bronchus. Five-minute clamping tests of the right pulmonary artery were performed before ischemia and 30 min after reperfusion. During the test, left pulmonary vascular resistance (L-PVR), cardiac output (CO), and arterial oxygen pressure (PaO(2)) were measured. The lung specimens were simultaneously harvested for wet-to-dry weight ratio (WDR) measurements, histopathological studies, and polymorphonuclear neutrophil (PMN) counts. Serum thromboxane (Tx) B(2) and 6-keto-prostaglandin (PG) F(1alpha) (stable metabolites of TxA(2) and PGI(2), respectively) were also measured 30 min after reperfusion.
Results:
L-PVR, CO, PaO(2), and WDR were significantly (P < 0.05) better in the FK group than in the control group. Histological tissue edema was mild, and PMN infiltration was significantly (P < 0.05) reduced in the FK group compared to the control group. The serum TxB(2) levels were significantly (P < 0.05) lower in the FK group than in the control group, while 6-keto-PGF(1alpha) levels were not significantly (P < 0.05) reduced. Two-day survival rate was significantly (P < 0.05) better in the FK group than in the control group.
Conclusions:
FK has protective effects on pulmonary I/R injury stemming from marked inhibition of TxA(2).
Insights
FK, a COX-2 inhibitor, significantly reduced lung injury after ischemia-reperfusion in dogs by inhibiting thromboxane A2. This finding offers a potential therapeutic strategy for pulmonary ischemia-reperfusion injury.
Area of Science:
- Cardiovascular Research
- Pulmonary Medicine
- Pharmacology
Background:
- Investigating the impact of selective COX-2 inhibitors on lung injury.
- Focusing on warm ischemia-reperfusion (I/R) injury in a canine model.
Purpose of the Study:
- To evaluate the protective effects of FK3311, a selective COX-2 inhibitor, against pulmonary I/R injury.
- To assess FK3311's influence on physiological parameters and biochemical markers post-injury.
Main Methods:
- Utilizing a canine model with induced warm pulmonary I/R for 3 hours.
- Administering FK3311 (1 mg/kg) pre-ischemia and pre-reperfusion versus a vehicle control.
- Measuring pulmonary vascular resistance, cardiac output, arterial oxygen pressure, and lung wet-to-dry weight ratio.
Main Results:
- FK3311 treatment significantly improved pulmonary vascular resistance, cardiac output, arterial oxygenation, and reduced lung edema.
- Histological analysis showed decreased polymorphonuclear neutrophil infiltration and tissue edema in the FK3311 group.
- Serum thromboxane B2 levels were significantly lower, while 6-keto-prostaglandin F1alpha levels showed no significant change.
Conclusions:
- FK3311 demonstrates significant protective effects against pulmonary I/R injury in canines.
- The protective mechanism is strongly linked to the marked inhibition of thromboxane A2 production.
- FK3311 represents a potential therapeutic agent for managing pulmonary I/R injury.